National Cancer Institute (U.S.)
"National Cancer Institute (U.S.)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
| Descriptor ID |
D054547
|
| MeSH Number(s) |
I01.409.418.750.600.650.496.150 N03.540.052.750.150 N03.540.348.500.500.600.650.496.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "National Cancer Institute (U.S.)".
Below are MeSH descriptors whose meaning is more specific than "National Cancer Institute (U.S.)".
This graph shows the total number of publications written about "National Cancer Institute (U.S.)" by people in this website by year, and whether "National Cancer Institute (U.S.)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 6 | 7 |
| 2009 | 0 | 9 | 9 |
| 2010 | 0 | 9 | 9 |
| 2011 | 2 | 5 | 7 |
| 2012 | 0 | 4 | 4 |
| 2013 | 2 | 4 | 6 |
| 2014 | 0 | 8 | 8 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 7 | 9 |
| 2017 | 3 | 6 | 9 |
| 2018 | 3 | 7 | 10 |
| 2019 | 1 | 7 | 8 |
| 2020 | 1 | 10 | 11 |
| 2021 | 0 | 10 | 10 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 9 | 9 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "National Cancer Institute (U.S.)" by people in Profiles.
-
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. J Natl Cancer Inst. 2024 Nov 01; 116(11):1721-1729.
-
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther. 2024 Jul 02; 23(7):924-938.
-
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
-
Evaluation of the National Cancer Institute (NCI) Pathway to Independence Award (K99/R00) Program. J Cancer Educ. 2024 Oct; 39(5):490-503.
-
NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer. J Natl Cancer Inst. 2023 12 06; 115(12):1457-1464.
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
-
An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals. J Natl Cancer Inst. 2023 10 09; 115(10):1115-1120.
-
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership. J Natl Cancer Inst. 2023 10 09; 115(10):1132-1138.
-
Global oncology research and training at US National Cancer Institute-designated cancer centres: results of the 2021 Global Oncology Survey. Lancet Oncol. 2023 10; 24(10):e407-e414.
-
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 09 07; 115(9):1001-1010.